Vertex tiptoes further into Duchenne research with Tevard deal
Bio Pharma Dive
FEBRUARY 28, 2023
An alliance with the startup brings Vertex an RNA-based medicine for the disease, adding to a portfolio that already includes a gene editing treatment.
Let's personalize your content